Neuron23 closes $96.5 million Series D financing round led by a healthcare investor to advance NEU-411 in Parkinson's disease.

Jun 24, 2025•about 2 months ago

Amount Raised

$96.5 Million

Round Type

series d

San FranciscoBiotechnology

Investors

Acorn BioventuresHbm Healthcare Investments (Cayman) Ltd.Kleiner PerkinsBlue OwlRedmile GroupSoft Bank Vision Fund 2Westlake Village Bio Partners

Description

Neuron23 Inc. announced the closing of a $96.5 million Series D financing round, led by a healthcare investor. Existing investors include Westlake Village BioPartners, SoftBank Vision Fund 2, and others. This funding supports the NEULARK trial evaluating NEU-411 for early Parkinson’s disease

Company Information

Company

Neuron23

Location

San Francisco, California, United States

About

Neuron23™ Inc. is a leading clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The Company’s focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends